Project Grant R01NS134798
Award Date
9/15/24
Completion Date
8/31/28
Dollars Obligated
$649K
Federal Agency
National Institute of Neurological Disorders and Stroke
Federal Grant Program
93.853
Assistance Type
Project Grant
Place of Performance
La Jolla, CA 92093, USA
Similar Awards
This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, is focused on assessing the role of the SMARCA5 protein in glioblastoma, an incurable brain tumor. The $638,697 award to the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University aims to determine how inhibiting SMARCA5 can force glioma stem cells to...
This $195,896 Project Grant, awarded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports research to define the circuit connectivity between glioblastoma, a fatal brain cancer, and diverse neuronal populations in the mouse brain. The research aims to elucidate the role of cholinergic neuromodulatory inputs in regulating glioma progression, with the goal of...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under CFDA program 93.853 "Extramural Research Programs in the Neurosciences and Neurological Disorders", is funding research to investigate how physical force regulates gene expression and transcriptional states in glioblastoma (GBM), the most common malignant brain tumor. The $452,375 award to The Trustees of Columbia University will leverage the diverse landscape of tissue stiffness in...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $687,279 to Beth Israel Deaconess Medical Center, Inc. (BIDMC) to conduct research on dissecting the orchestrated immune responses to glioblastoma within the native tissue microenvironment. The goal is to improve treatment outcomes by advancing the understanding of the diversity,...
This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $449,203 to Mayo Clinic Jacksonville (A Nonprofit Corporation) to investigate the mechanisms by which the subventricular zone (SVZ) neurogenic niche influences the malignancy of glioblastoma (GBM) brain tumors. The project aims to leverage novel cell-specific proteomic...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), part of the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) grant program, will fund research to target cell-scaffolding proteins that contribute to radioresistance in glioblastoma, an aggressive brain cancer. The $448,250 award to The Research Foundation For The State University Of New York, operating as Upstate Medical Center, will support a 2-year...
The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $717,802 Project Grant under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) to the University of Georgia Research Foundation, Inc. The grant supports research aimed at elucidating the cellular and molecular mechanisms underlying the development of a subtype of high-grade glioma brain tumors known as HGG-G34. Specifically, the research project seeks to unravel the...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $595,047.00 to the University of California, Los Angeles (UCLA) to investigate non-apoptotic forms of cell death in glioblastoma (GBM), the most deadly primary brain tumor in adults. The key objectives are to: 1) Define the mechanistic basis for GBM sensitivity to a novel form of...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $628,373 to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to conduct research on understanding how endogenous dendritic cells drive T cell activation and expansion in glioblastoma. The award period runs from August 1, 2025 to June 30,...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $472,124 to Beth Israel Deaconess Medical Center, Inc. to conduct exploratory studies on the role of TREM1 and TREM2 receptors in the immune response to glioblastoma, an aggressive form of brain cancer. The research aims to use a novel mouse model of glioblastoma to investigate how...